Canada Pension Plan Investment Board Takes $496,000 Position in Amylyx Pharmaceuticals, Inc. $AMLX

Canada Pension Plan Investment Board bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 27,600 shares of the company’s stock, valued at approximately $496,000.

Other large investors have also recently bought and sold shares of the company. Meeder Asset Management Inc. bought a new stake in Amylyx Pharmaceuticals in the fourth quarter valued at approximately $25,000. KBC Group NV bought a new position in shares of Amylyx Pharmaceuticals during the 1st quarter worth approximately $26,000. California State Teachers Retirement System acquired a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $28,000. State of Wyoming bought a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $40,000. Finally, Legal & General Group Plc bought a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $47,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider owned 194,090 shares in the company, valued at approximately $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX opened at $34.49 on Thursday. The business’s 50 day simple moving average is $23.58 and its 200 day simple moving average is $17.93. Amylyx Pharmaceuticals, Inc. has a 1 year low of $9.61 and a 1 year high of $41.14. The company has a market capitalization of $3.84 billion, a P/E ratio of -24.12 and a beta of -0.13.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, sell-side analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Analysts Set New Price Targets

AMLX has been the subject of a number of research reports. Mizuho raised their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. HC Wainwright upped their price target on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Robert W. Baird increased their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday, August 19th. Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 17th. Finally, Citigroup raised their price objective on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $36.50.

About Amylyx Pharmaceuticals